EGFR Inhibitor Response Prediction via Gene Expression Analysis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer therapies, particularly those targeting EGFR, often result in toxicity and inefficiency due to their non-specific action on rapidly dividing cells, leading to unnecessary exposure and delayed treatment with more effective drugs, highlighting the need for predictive diagnostics to identify responsive patients.
Innovation Solution
The development of methods and compositions to determine the likelihood of a patient's response to EGFR inhibitor therapy by measuring normalized expression levels of specific response indicator genes, such as ATP5E, TITF1, and BRCA1, to predict beneficial responses and tailor treatment approaches.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If targeted EGFR inhibitor therapy is administered, then treatment effectiveness is improved for responsive patients, but toxicity and unnecessary exposure occur for non-responsive patients
Solution Approach 1:
The patent applies preliminary action by performing gene expression analysis before administering EGFR inhibitor therapy. The method measures expression levels of specific genes (such as EGFR, HER2, and other biomarkers) to predict patient response in advance, allowing clinicians to identify responsive patients before treatment begins. This preliminary diagnostic step prevents unnecessary toxicity exposure by screening out non-responsive patients who would not benefit from the therapy.
2Adaptability or versatility
If gene expression analysis is performed to predict treatment response, then treatment personalization is improved, but diagnostic complexity and cost increase
Solution Approach 1:
The patent applies segmentation by dividing the diagnostic process into distinct components: identifying specific gene targets (EGFR, HER2, and other biomarkers), measuring their expression levels separately, and evaluating each gene's contribution to treatment response prediction. This segmented approach allows for systematic analysis of multiple biomarkers while maintaining clarity in interpretation, making the complex diagnostic process more manageable and implementable in clinical settings.
Data Source
Figure 1
Figure 1
Figure 1
AI summary
The present invention provides methods and compositions to facilitate determining whether an EGFR-expressing cancer in an individual is an EGFR inhibitor-responsive cancer, as well as methods for determining the likelihood that a patient having an EGFR-expressing cancer will exhibit a beneficial response to an EGFR inhibitor therapy. The methods generally involve determining a normalized expression level of a gene product that correlates with EGFR inhibitor responsiveness.